首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Circulating Troponin As Measured by a Sensitive Assay for Cardiovascular Risk Assessment in Primary Prevention
【24h】

Circulating Troponin As Measured by a Sensitive Assay for Cardiovascular Risk Assessment in Primary Prevention

机译:初级诊断中心血管疾病风险评估的敏感检测方法所测定的循环肌钙蛋白

获取原文
           

摘要

BACKGROUND: Measuring circulating cardiac troponin using novel sensitive assays has revealed that even minute elevations are associated with increased mortality in patients with coronary artery disease or even in the general population. Less well defined, however, is the incremental value of measuring circulating cardiac troponin I (cTnI) by a sensitive assay for risk assessment in primary prevention.METHODS: We measured circulating concentrations of cTnI, N-terminal pro–B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hsCRP) in 5388 individuals free of known cardiovascular disease recruited into the DETECT study, a prospective longitudinal population-based cohort study. We determined the prognostic implications for incident major adverse cardiovascular events (MACE) during 5 years of follow-up.RESULTS: Circulating cTnI was detectable in 19% of the subjects. Increased cTnI concentrations were associated with established risk factors for atherosclerosis and demonstrated a graded relationship with all-cause mortality and incident MACE during 5-year follow-up. A single measurement of cTnI significantly improved risk prediction over established risk factors, and also added prognostic information, when adjusted for serum concentrations of NT-proBNP and hsCRP.CONCLUSIONS: Minute increases in cTnI are associated with increased mortality and incident MACE in a large primary prevention cohort and, thus, identify contributors to cardiovascular risk not fully captured by traditional risk factor assessment.
机译:背景:使用新型灵敏测定法测量循环心肌肌钙蛋白已显示,冠心病患者或什至普通人群中,甚至微小的升高都会增加死亡率。然而,定义不明确的是通过敏感性分析测量循环心肌肌钙蛋白I(cTnI)的增量值,以进行一级预防中的风险评估。方法:我们测量了cTnI,N末端前B型利尿钠肽的循环浓度( NT-proBNP)和高敏感性C反应蛋白(hsCRP)在5388名无已知心血管疾病的个体中被纳入DETECT研究中,该研究是一项基于纵向人群的前瞻性队列研究。我们确定了在5年的随访期间对重大心血管不良事件(MACE)的预后影响。结果:在19%的受试者中可检测到循环cTnI。升高的cTnI浓度与确定的动脉粥样硬化危险因素相关,并在5年的随访期间显示出与全因死亡率和MACE发生的分级关系。调整NTT-proBNP和hsCRP的血清浓度后,单次测量cTnI可以显着改善已建立的危险因素的风险预测,并且还可以增加预后信息。结论:cTnI的微小升高与大型原发性疾病的死亡率和发生的MACE升高相关预防队列,从而确定传统危险因素评估未完全涵盖的心血管危险因素。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号